NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
December 12, 2025 in Home Page, NanOlogy Press Release

NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor

NanOlogy 13 Like Post Comments Off on NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor

PRESS RELEASE NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor Next Generation Intratumoral Technology Targets Diffuse Intrinsic Pontine Glioma Investigational New Drug ...

Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal